British medical bulletin
-
British medical bulletin · Dec 2023
ReviewSmall interfering RNAs in the management of human osteoporosis.
Osteoporosis results in reduced bone mass and consequent bone fragility. Small interfering RNAs (siRNAs) can be used for therapeutic purposes, as molecular targets or as useful markers to test new therapies. ⋯ Despite the predictability of pharmacological response of siRNA in vitro, similar responses cannot be expected in vivo.
-
British medical bulletin · Dec 2023
Addressing the challenges facing the paramedic profession in the United Kingdom.
The paramedic profession within the United Kingdom has been evolving at pace over the last 20 years. While they are most associated with their work in ambulance services, paramedics are now found throughout a range of clinical and academic settings. ⋯ Research to establish perspectives of and about the paramedic profession may assist in developing an understanding of identity and its place within the wider healthcare workforce.
-
British medical bulletin · Sep 2023
Meta AnalysisEfficacy of hydrodilatation in frozen shoulder: a systematic review and meta-analysis.
It is unclear whether hydrodilatation is beneficial in the management of frozen shoulder compared with other common conservative management modalities. This systematic review evaluates the efficacy of hydrodilatation for the management of frozen shoulder. ⋯ Although current evidence suggests that hydrodilatation provides a transient improvement in disability in patients with frozen shoulder, its clinical relevance remains unclear. Further research is necessary to establish its role in the management of the condition.
-
British medical bulletin · Sep 2023
Meta AnalysisDrug repurposing for COVID-19: current evidence from randomized controlled adaptive platform trials and living systematic reviews.
The coronavirus disease 2019 (COVID-19) pandemic resulted in a race to develop effective treatments largely through drug repurposing via adaptive platform trials on a global scale. Drug repurposing trials have focused on potential antiviral therapies aimed at preventing viral replication, anti-inflammatory agents, antithrombotic agents and immune modulators through a number of adaptive platform trials. Living systematic reviews have also enabled evidence synthesis and network meta-analysis as clinical trial data emerge globally. ⋯ The timing of therapeutic interventions based on postulated mechanisms of action and the selection of clinically meaningful primary end points remain important considerations in the design and implementation of COVID-19 therapeutic trials.